灵康药业公告称，2026年2月10日，公司控股股东灵康控股部分股份解除质押，数量为4965.96万股，占 其持有公司股份总数的14.62%，占公司总股本的6.89%。灵康控股直接及间接持有公司股份33965.28万 股，占公司总股本的47.09%。解除质押后，其剩余被质押股份数量为5400.00万股，占其所持股份比例 为15.90%，占公司总股本比例为7.49%。经确认，解除质押的股份暂无后续质押计划。 ...

Financial Performance - For the fiscal year 2025, the company expects a net profit attributable to shareholders of approximately -127 million yuan, a year-on-year reduction in loss of about 2.88%[2] - The expected operating revenue for 2025 is around 365 million yuan, representing a year-on-year decline of approximately 3.89%[2] - The revenue from the main business, after excluding unrelated income, is projected to be about 345 million yuan, down approximately 6.64% year-on-year[2] - The preliminary financial results have not yet been audited by registered accountants[2] Product Revenue Expectations - Sales revenue from anti-infection products is expected to decline by around 70% due to the transition period of centralized procurement and price drops[3] - Revenue from cardiovascular products is anticipated to decrease by about 30% due to increased competition from newly approved products[3] Operational Challenges - The company's capacity utilization rate is low, leading to higher fixed costs per unit and significant pressure on overall profits[3] Business Expansion - The company is expanding its pharmaceutical agency and distribution business, which has seen substantial revenue growth compared to the previous year[3] Credit Rating - The company's credit rating remains at A- with a stable outlook, as assessed by Dongfang Jincheng[1]

Core Viewpoint - Lingkang Pharmaceutical expects to achieve an annual revenue of approximately 365 million yuan in 2025, representing a year-on-year decline of about 3.89% [1] Revenue Summary - The company's revenue, after excluding related income, is projected to be around 345 million yuan, reflecting a year-on-year decrease of approximately 6.64% [1] Profit Summary - The net profit attributable to the parent company's owners is estimated to be around -127 million yuan, indicating a year-on-year reduction in losses of about 2.88% [1] - The non-recurring net profit is expected to be around -147 million yuan, showing a year-on-year reduction in losses of approximately 18.41% [1] Performance Drivers - The performance changes are primarily attributed to the transition period of the new and old procurement standards for anti-infection products, price reductions for winning varieties, intensified competition in cardiovascular products, low capacity utilization, and significant growth in revenue from pharmaceutical agency and distribution businesses [1]

Group 1 - The company has decided not to exercise the downward adjustment of the conversion price for "Lingkang Convertible Bonds" despite triggering conditions due to stock price performance [2][6][36] - The current conversion price is set at 6.50 yuan per share, down from the initial price of 8.81 yuan per share, with previous adjustments made due to profit distribution and other factors [3][4][5] - The board will reassess the situation after a three-month period, from January 31, 2026, to April 30, 2026, and will hold another meeting if the adjustment conditions are triggered again [2][6][36] Group 2 - The company plans to change the purpose of repurchased shares from a 50% allocation for employee stock ownership plans and 50% for equity incentives to cancellation and reduction of registered capital [8][10][12] - A total of 8,915,893 shares, representing 1.24% of the company's total share capital, will be canceled as part of this plan [9][13] - The decision to change the purpose of repurchased shares is aimed at enhancing long-term investor confidence and improving earnings per share [12][14][38]

Core Viewpoint - Lingkang Pharmaceutical announced a change in the purpose of its repurchased shares, shifting from an employee stock ownership plan and equity incentive to cancellation and reduction of registered capital [1] Summary by Relevant Sections - **Company Announcement** - On January 30, 2026, Lingkang Pharmaceutical will hold its sixth meeting of the fifth board of directors to review the proposal regarding the change in the purpose of repurchased shares and the cancellation of shares [1] - **Share Repurchase Details** - The company has 8,915,893 shares in its repurchase account that are currently unused [1] - **Change in Usage of Shares** - The intended use of the repurchased shares has been altered from "50% for employee stock ownership plan and 50% for equity incentives" to "for cancellation and reduction of registered capital" [1]

证券代码：603669 证券简称：灵康药业 公告编号：2026-005 灵康药业集团股份有限公司 关于变更回购股份用途并注销 暨减少注册资本的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购股份用途变更情况：灵康药业集团股份有限公司（以下简称"公司"） 拟将存放于回购专用证券账户中已回购尚未使用的股份用途进行变更，由"50% 用于员工持股计划，50%用于股权激励"变更为"用于注销并减少注册资本"。 本次拟变更用途并注销的股份共计 8,915,893 股，占公司当前总股本的 比例为 1.24%。 1 持股计划或者股权激励，回购期限自董事会审议通过回购股份方案之日起不超过 12 个月。具体内容详见公司分别于 2022 年 3 月 10 日和 2022 年 3 月 16 日在上 海证券交易所网站披露的《关于以集中竞价交易方式回购公司股份方案的公告》 （公告编号：2022-010）、《灵康药业集团股份有限公司回购报告书》（2022-012）。 （二）回购股份实施情况 2022 年 3 月 29 日公司首 ...

证券代码：603669 证券简称：灵康药业 公告编号：2026-007 2026年第一次临时股东会 召开的日期时间：2026 年 3 月 5 日 14 点 30 分 召开地点：浙江省杭州市上城区民心路 100 号万银国际大厦 27 层，浙江灵 康药业有限公司会议室 (五) 网络投票的系统、起止日期和投票时间。 灵康药业集团股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 股东会召开日期：2026年3月5日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 3 月 5 日 至2026 年 3 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 ...

证券代码：603669 证券简称：灵康药业 公告编号：2026-004 灵康药业集团股份有限公司 第五届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 灵康药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会议 通知于 2026 年 1 月 26 日以电话、电子邮件等形式发出，会议于 2026 年 1 月 30 日在浙江灵康药业有限公司会议室以现场结合通讯方式召开。会议由董事长陶灵 萍召集并主持，应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人。公 司高级管理人员列席了会议。本次会议的召集、召开和表决程序符合有关法律、 法规和《公司章程》的规定，会议形成的决议合法有效。 具体内容详见同日披露于上海证券交易所网站上（www.sse.com.cn）的公告。 2、审议通过了《关于变更回购股份用途并注销暨减少注册资本的议案》 根据《中华人民共和国公司法》《上海证券交易所股票上市规则》《上海证券 交易所上市公司自律监管指引第 7 号——回购股份》等法律法规、规范 ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2026-006 | | --- | --- | --- | | 证券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 截至 2026 年 1 月 30 日，灵康药业集团股份有限公司（以下简称"灵康 药业"或"本公司"）股价已出现连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的 85%之情形，已触发"灵康转债"的转股价格向下修正 条款。 经公司第五届董事会第六次会议审议通过，公司董事会决议本次不行使 "灵康转债"的转股价格向下修正的权利，且在未来 3 个月内（2026 年 1 月 31 日至 2026 年 4 月 30 日），如再次触及可转债转股价格向下修正条款，亦不提出 向下修正方案，从 2026 年 5 月 6 日开始重新起算，若再次触发"灵康转债"的 转股价格向下修正条件，届时公司董事会将再次召开会议审议是否行使"灵康转 债"的转股价格向下修正权利。 一、可转换公司债券的基本情况 （一）经中国证券监督管理委员会证监许可[2020]2640 号文核准，灵康药业 集团股份有限公司于 2020 年 1 ...

Group 1 - The company expects a net profit attributable to shareholders of approximately -127 million yuan for the year 2025, representing a reduction in losses of about 2.88% compared to the previous year [2][4] - The expected operating revenue for 2025 is around 365 million yuan, which is a decrease of approximately 3.89% year-on-year [4] - The main reasons for the anticipated losses include the inability of sales gross profit to cover operating expenses, intensified market competition due to ongoing drug procurement policies, and a significant decline in sales revenue from certain product categories [7] Group 2 - The company reported a net profit attributable to shareholders of -130.76 million yuan for the previous year, with a total profit of -127.73 million yuan [6] - The previous year's operating revenue was 379.78 million yuan, with a loss per share of -0.18 yuan [6] - The company is expanding its pharmaceutical agency and distribution business, which has seen significant revenue growth compared to the previous year [7] Group 3 - The company has issued convertible bonds with a total amount of 525 million yuan, and the current conversion price is 6.50 yuan per share [12][14] - If the stock price remains below 85% of the conversion price for a specified period, it may trigger a downward adjustment of the conversion price [12][17] - The company will hold a board meeting to decide on any adjustments to the conversion price if the conditions are met [17]